tiprankstipranks
Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025
PremiumThe FlyCapricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025
2d ago
Prothena partner Roche PADOVA study misses primary endpoint
Premium
The Fly
Prothena partner Roche PADOVA study misses primary endpoint
2d ago
Prothena Corporation Reports Q3 2024 Financial Results
Premium
Company Announcements
Prothena Corporation Reports Q3 2024 Financial Results
1M ago
Prothena selloff ‘misplaced,’ brings buying opportunity, says H.C. Wainwright
PremiumThe FlyProthena selloff ‘misplaced,’ brings buying opportunity, says H.C. Wainwright
3M ago
Prothena’s downside move may be excessive, says RBC Capital
Premium
The Fly
Prothena’s downside move may be excessive, says RBC Capital
3M ago
Oppenheimer says Prothena’s Garren left for ‘amazing opportunity’
Premium
The Fly
Oppenheimer says Prothena’s Garren left for ‘amazing opportunity’
3M ago
Prothena price target lowered to $62 from $66 at Oppenheimer
PremiumThe FlyProthena price target lowered to $62 from $66 at Oppenheimer
4M ago
3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)
Premium
Market News
3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)
4M ago
Prothena price target lowered to $24 from $28 at RBC Capital
Premium
The Fly
Prothena price target lowered to $24 from $28 at RBC Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100